Related Experiment Video

Updated: Jun 5, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Prevention of restenosis future directions

C Bauters1, E Van Belle, T Meurice

  • 1Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Boulevard du Professeur J Leclercq,59037 Lille Cedex, France.

Trends in Cardiovascular Medicine
|January 18, 2011
PubMed

Insights

Restenosis, a complication of coronary angioplasty, is primarily caused by neointimal hyperplasia. Coronary stenting combined with drug therapy may offer a future solution to prevent this arterial narrowing.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology

Background:

  • Restenosis is a significant limitation following percutaneous transluminal coronary angioplasty (PTCA).
  • Vascular remodeling and neointimal hyperplasia are key contributors to restenosis post-balloon angioplasty.
  • Previous pharmacological trials for restenosis prevention have largely failed in human studies.

Purpose of the Study:

  • To explore the potential of locally delivered drugs for restenosis prevention.
  • To evaluate the role of coronary stenting in reducing restenosis risk.
  • To investigate therapies targeting neointimal hyperplasia for in-stent restenosis.

Main Methods:

  • Review of clinical trials and randomized studies on PTCA and coronary stenting.
  • Assessment of local drug delivery systems and therapeutic agents.
  • Analysis of mechanisms underlying restenosis after balloon angioplasty versus stenting.

Main Results:

  • Coronary stenting has demonstrated a reduced risk of restenosis compared to balloon angioplasty alone.
  • Neointimal hyperplasia is the primary cause of restenosis following coronary stenting.
  • Restenosis within stents may be more amenable to therapies inhibiting neointimal hyperplasia.

Conclusions:

  • The combination of mechanical devices (stents) and pharmacological approaches offers a promising strategy for future restenosis prevention.
  • Inhibiting neointimal hyperplasia is crucial for managing restenosis after coronary stenting.
  • Optimizing lumen diameter and preventing vessel constriction are key goals in interventional cardiology.

More Related Videos

Development of a Murine Model for Femoral Artery Anastomotic Stenosis05:42

Development of a Murine Model for Femoral Artery Anastomotic Stenosis

Published on: April 18, 2025

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...